G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Finance News Network
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • G Medical Innovations (GMV) has expanded its agreement with HSC Technology to offer its remote patient monitoring services in Australia and New Zealand
  • This expansion allows hospitals and healthcare providers to remotely monitor their patients 24 hours a day
  • Patients who are enrolled in the service will be charged between $19 and $35 per month, which will be shared between G Medical, HSC Technology, and third-party providers
  • G Medical is up 6.60 per cent on the market and shares are currently trading for 5.7 cents each

G Medical Innovations (GMV) has expanded its agreement with HSC Technology to offer its remote patient monitoring services in Australia and New Zealand.

This extension follows a non-exclusive agreement secured in April where G Medical integrated and distributed its Prizma device via HSC’s uVue telehealth platform to monitor the vital signs of elderly patients in a nursing home.

It also allows G Medical to introduce its 24-hour remote patient monitoring service to hospitals and other healthcare providers.

“The launch of a 24-hour remote patient monitoring service in Australia with a trusted and respected partner like HSC presents us with yet another avenue to grow our patient services infrastructure and recurring revenues,” Director Dr Brendan de Kauwe said.

“HSC Technology Group will unlock an established network of healthcare providers and resellers, as well as a leading technology platform that G Medical can leverage quickly to drive uptake in Australia and New Zealand,” he added.

Patients enrolled in the service will be charged between $19 and $35 per month, which will be shared between G Medical, HSC Technology, and third-party providers.

Additionally, this will allow G Medical to strengthen its footprint in Australia and New Zealand and unlock additional markets for its Prizma and Patch devices.

“Australia and New Zealand are important markets for G Medical and we believe we can establish a solid business here with the right partners,” CEO and Managing Director Dr Yacov Geva commented.

G Medical is up 6.60 per cent on the market and shares are trading for 5.7 cents each at 1:30 pm AEST.

GMV by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…

4DMedical partners with West Los Angeles VA Medical Center for Veteran lung imaging study

Respiratory imaging technology company, 4DMedical (ASX:4DX) has entered into a research agreement with the West Los…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…